Purpose of Review <p>This review provides a comprehensive, critically appraised summary of recent research on the prevention and management of ventriculitis, with contextualization within the broader pre-2020 evidence base.</p> Recent Findings <p>Beyond confirming established risk factors such as duration of central nervous system (CNS) devices and cerebrospinal fluid (CSF) leaks, recent studies have refined risk stratification by identifying procedural and patient-level contributors. Advanced diagnostics — notably multiplex polymerase chain reaction (PCR) panels and metagenomic next-generation sequencing (mNGS) — have accelerated and broadened pathogen identification, revealing polymicrobial and fungal contributions previously under-appreciated. Novel CSF biomarkers (presepsin, HMGB-1, cell index, and cytokine profiles including the IL-17/IL-23 axis) offer incremental diagnostic and prognostic value. Management of multidrug-resistant (MDR) organisms increasingly relies on intraventricular antibiotic protocols, pharmacokinetically informed systemic dosing, and neuroendoscopic interventions. Evidence-based care bundles have continued to demonstrate sustained reductions in infection rates in long-term, multi-centre cohorts.</p> Summary <p>Current literature offers more granular risk stratification, improved etiological characterization via molecular diagnostics, emerging biomarkers, refined treatment strategies for complex infections, and robust real-world evidence for prevention bundles. However, methodological heterogeneity — inconsistent definitions, predominance of single-centre observational designs, and limited evidence-quality appraisal — continues to limit the generalisability of findings.</p>